Quantcast
Last updated on April 15, 2014 at 21:23 EDT

Latest biopharmaceutical Stories

2014-04-15 16:27:51

AUSTIN, Texas, April 15, 2014 /PRNewswire/ -- XBiotech announced today that Robert Lindsey has joined the Company as Senior Vice President Corporate Development & General Counsel. Mr. Lindsey joins XBiotech from Dell where he served as Legal Director. In that capacity, Mr. Lindsey acted as the sole securities counsel for Dell and was the primary attorney responsible for the treasury, accounting, investor relations, corporate communications and internal audit groups. Most recently,...

2014-04-11 23:01:51

Transparency Market Research Report Added "Biosimilar And Follow-On Biologics Market - Global Industry Size, Share, Trends, Analysis And Forecasts 2012 - 2018" to its database. Browse Full Report - http://www.transparencymarketresearch.com/biosimilar-and-follow-on-biologics-market.html. Albany, New York, USA (PRWEB) April 11, 2014 There is a rising demand for low cost biological drugs. Commercial and regulatory developments are taking the follow-on biologics market to new...

2014-04-10 08:29:30

MONROVIA, Calif., April 10, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that the company has received a milestone payment from Merck, through a subsidiary, triggered by the initiation of a Phase 1 clinical trial for an undisclosed biologic drug candidate that uses Xencor's XmAb® antibody...

2014-04-10 08:28:53

NEW YORK, April 10, 2014 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM), is an emerging biopharmaceutical company focused on the $54 billion market for cancer drugs. The Company's most advanced products are Actimab(TM)-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia (AML) and Iomab(TM)-B, an antibody-drug construct containing iodine 131 (I-131), used in myeloconditioning for hematopoietic...

2014-04-02 16:30:36

SEATTLE, and COPHENHAGEN, Denmark, April 2, 2014 /PRNewswire/ -- CMC Biologics, a leading global contract manufacturing organization known for technical excellence and customer satisfaction in biopharmaceutical development and commercial manufacture of protein based therapeutics, was recognized again in 2014 for innovation, quality and reliability by Life Science Leader at an awards ceremony at DCAT Week14 in New York last month....

2014-04-01 08:29:19

Expanding Product Offerings; Building IP Portfolio; Seeking Global Marketing Partners NEW YORK, April 1, 2014 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) provided investors with a strategic update on its programs and plans for its proprietary mucoadhesive hydrogel platform technology. Access' patented technology surrounds a unique aqueous pseudoplastic liquid with a defined viscosity range, which is beneficial to the treatment of disorders of mucosal tissue, and...

2014-03-31 23:32:32

Nominations Deadline: June 27, 2014; Open to all. Awards Ceremony: In conjunction with BioProcess International Conference & Exhibition, October 22, 2014, Boston, MA. New York, NY (PRWEB) March 31, 2014 BioProcess International (BPI), a business-to-business publication dedicated to delivering cutting-edge information focused on the development and manufacture of biopharmaceuticals and therapeutics, announces the 2014 BioProcess International Awards Dinner and Ceremony will take place...

2014-03-31 16:27:39

LA JOLLA, Calif., March 31, 2014 /PRNewswire/ -- Auspex Pharmaceuticals, Inc. (Nasdaq: ASPX), a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, today announced that the Company was added to the Russell 2000® Index (as well as the larger Russell 3000® Index) at the close of market on March 31, 2014 as part of the quarterly Initial Public Offering (IPO) update to the Russell indexes. The...

2014-03-31 08:28:28

More than half of biopharmaceutical companies surveyed use a Strategic Partnership model BOSTON, March 31, 2014 /PRNewswire/ -- PAREXEL International (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today released Strategic Partnerships 2014: Driving Biopharmaceutical Outsourcing Effectiveness, at the 23rd Annual Partnerships in Clinical Trials Conference in Las Vegas, NV. It provides compelling insights that highlight the value of these multi-year, highly integrated...

2014-03-27 12:31:03

LONDON, March 27, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Global and China Monoclonal Antibody Industry Report, 2013-2017 Currently, monoclonal antibody agents have been successfully used in the treatment of tumors, cancers and other serious diseases as a heavyweight in the biopharmaceutical industry. In 2009-2012, the market size of monoclonal antibody agents grew at a CAGR of 13%, far higher than the overall growth rate of...